Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Inclusion Criteria: * Healthy subjects or subjects with AD as defined by the Hanifen and Rajka criteria and with at least mild disease activity (IGA \>2) for the whole body * AD lesions amenable to cutaneous treatment located on the trunk and/or limbs (only for AD subjects) * Male subjects aged between 18 and 65 years with a body mass index (BMI) between 19.0 and 32.0 kg/m2 inclusive Exclusion Criteria: * Subjects who currently suffer from, or show signs of eczema or other skin lesions (only for healthy subjects) * Subjects who are still participating in a clinical trial (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational product or a marketed drug product within the past 3 months prior to the first dosing occasion. * Subjects with known immunocompromised state due to treatment with immunosuppressive drugs or due to history of a disease leading to immunocompromised status. * History of or current cardiac arrhythmic disorder * Subjects with a current active malignancy or a history of malignancy in remission for less than 5 years except excised skin (not melanoma) and cervical cancer. * Subjects who have any clinically significant allergic disease (excluding non- active hayfever) as determined by the Investigator